These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 11267171

  • 21. Anti-CD25 therapy impairs donor-specific Th1 and Th2 cytokine-producing peripheral blood cells after clinical heart transplantation.
    van Besouw NM, Balk AH, van Vliet M, van der Meide PH, Maat AP, van Gelder T, Baan CC, Weimar W.
    Transplant Proc; 2002 Nov; 34(7):2942-3. PubMed ID: 12431667
    [No Abstract] [Full Text] [Related]

  • 22. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J, Marcén R, Ortuño J.
    Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract] [Full Text] [Related]

  • 23. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR, Faulds D.
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [Abstract] [Full Text] [Related]

  • 24. Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants.
    Carreño MR, Kato T, Weppler D, Mathew JM, Fuller L, Gomez C, Salman F, Garcia-Morales R, Ciancio G, Burke GW, Esquenazi V, Miller J, Tzakis AG.
    Transplant Proc; 2001 Dec; 33(1-2):1015-7. PubMed ID: 11267170
    [No Abstract] [Full Text] [Related]

  • 25. Immunosuppression in cardiac transplantation.
    Hosenpud JD.
    N Engl J Med; 2005 Jun 30; 352(26):2749-50. PubMed ID: 15987926
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. IL-2 receptor blockers in liver transplantation: initial experience with daclizumab in Chile.
    Innocenti F, Humeres R, Zamboni M, Sanhueza E, Zapata R, Hepp J, Rius M.
    Transplant Proc; 2003 Nov 30; 35(7):2520-1. PubMed ID: 14612001
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
    Ciancio G, Burke GW, Suzart K, Vaidya A, Roth D, Kupin W, Mattiazzi A, Rosen A, Esquenazi V, Miller J.
    Transplant Proc; 2003 Mar 30; 35(2):873-4. PubMed ID: 12644172
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The efficacy of daclizumab for intestinal transplantation: preliminary report.
    Abu-Elmagd K, Fung J, McGhee W, Martin D, Mazariegos G, Schaefer N, Demetris J, Starzl TE, Reyes J.
    Transplant Proc; 2000 Sep 30; 32(6):1195-6. PubMed ID: 10995903
    [No Abstract] [Full Text] [Related]

  • 37. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A, Perez-Villa F, Vallejos I, Roig E.
    Transplant Proc; 2005 Nov 30; 37(9):4036-8. PubMed ID: 16386620
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Can antibody prophylaxis allow sparing of other immunosuppressives?
    Vincenti F, Grinyo J, Ramos E, Nashan B, Stuart F, Kuypers D, Brattstrom C, Cho S, Ekberg H, Johnson R.
    Transplant Proc; 1999 Nov 30; 31(1-2):1246-8. PubMed ID: 10083557
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.